# Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

> **NCT00332020** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 2457 (actual)

## Conditions studied

- Prevention
- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (BAY59-7939)
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00332020
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-05
- **Final completion:** 2007-06
- **Target enrollment:** 2457 (ACTUAL)
- **Last updated:** 2015-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332020, "Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00332020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*